177 related articles for article (PubMed ID: 19054383)
21. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
22. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
23. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
24. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.
Sánchez-Fructuoso AI; Ruiz JC; Calvo N; Rodrigo E; Perez-Flores I; Gómez-Alamillo C; Fernández-Pérez C; Arias M; Barrientos A
Transplantation; 2012 Feb; 93(4):398-405. PubMed ID: 22245871
[TBL] [Abstract][Full Text] [Related]
25. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
[TBL] [Abstract][Full Text] [Related]
28. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster.
Stypmann J; Engelen MA; Eckernkemper S; Amler S; Gunia S; Sindermann JR; Rothenburger M; Rukosujew A; Drees G; Welp HA
Transplant Proc; 2011 Jun; 43(5):1847-52. PubMed ID: 21693288
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
30. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
[TBL] [Abstract][Full Text] [Related]
32. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM;
Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433
[TBL] [Abstract][Full Text] [Related]
33. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
Engelen MA; Amler S; Welp H; Vahlhaus C; Gunia S; Sindermann JR; Rothenburger M; Stypmann J
Transplantation; 2011 May; 91(10):1159-65. PubMed ID: 21478817
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
Shenoy S; Hardinger KL; Crippin J; Desai N; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Transplantation; 2007 May; 83(10):1389-92. PubMed ID: 17519792
[TBL] [Abstract][Full Text] [Related]
36. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.
Gomez-Camarero J; Salcedo M; Rincon D; Lo Iacono O; Ripoll C; Hernando A; Sanz C; Clemente G; Bañares R
Transplantation; 2007 Sep; 84(6):786-91. PubMed ID: 17893613
[TBL] [Abstract][Full Text] [Related]
37. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
[TBL] [Abstract][Full Text] [Related]
39. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
Ruiz JC; Sanchez-Fructuoso A; Rodrigo E; Conesa J; Cotorruelo JG; Gómez-Alamillo C; Calvo N; Barrientos A; Arias M
Transplant Proc; 2006 Oct; 38(8):2424-6. PubMed ID: 17097956
[TBL] [Abstract][Full Text] [Related]
40. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients.
Vallin M; Guillaud O; Morard I; Gagnieu MC; Mentha G; Adham M; Morelon E; Boillot O; Giostra E; Dumortier J
Clin Transplant; 2011; 25(4):660-9. PubMed ID: 21158921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]